* H002 is a precision therapeutic candidate for the treatment of NSCLC, with broad spectrum and h...
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company...
* Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial * H002 Has Potential ...